- Home
- MXE vs STTK Comparison
MXE vs STTK Comparison
Compare MXE & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXE
- STTK
- Stock Information
- Founded
- MXE 1990
- STTK 2016
- Country
- MXE United States
- STTK United States
- Employees
- MXE N/A
- STTK N/A
- Industry
- MXE Finance Companies
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- MXE Finance
- STTK Health Care
- Exchange
- MXE Nasdaq
- STTK Nasdaq
- Market Cap
- MXE 42.5M
- STTK 37.6M
- IPO Year
- MXE N/A
- STTK 2020
- Fundamental
- Price
- MXE $9.97
- STTK $1.01
- Analyst Decision
- MXE
- STTK Hold
- Analyst Count
- MXE 0
- STTK 4
- Target Price
- MXE N/A
- STTK $3.00
- AVG Volume (30 Days)
- MXE 5.8K
- STTK 100.5K
- Earning Date
- MXE 01-01-0001
- STTK 05-01-2025
- Dividend Yield
- MXE 2.66%
- STTK N/A
- EPS Growth
- MXE N/A
- STTK N/A
- EPS
- MXE N/A
- STTK N/A
- Revenue
- MXE N/A
- STTK $4,606,000.00
- Revenue This Year
- MXE N/A
- STTK N/A
- Revenue Next Year
- MXE N/A
- STTK N/A
- P/E Ratio
- MXE N/A
- STTK N/A
- Revenue Growth
- MXE N/A
- STTK 69.65
- 52 Week Low
- MXE $8.40
- STTK $0.69
- 52 Week High
- MXE $11.51
- STTK $7.57
- Technical
- Relative Strength Index (RSI)
- MXE 62.55
- STTK 50.24
- Support Level
- MXE $9.94
- STTK $0.97
- Resistance Level
- MXE $10.08
- STTK $1.17
- Average True Range (ATR)
- MXE 0.14
- STTK 0.10
- MACD
- MXE -0.01
- STTK 0.01
- Stochastic Oscillator
- MXE 83.29
- STTK 45.21
About MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. It maintains an investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.